WM
47 programs · 46 companies
Programs
47
Companies
46
Trials
45
MOAs
35
FGFRiCAR-T CD19MALT1iDLL3 ADCVEGFiPRMT5iPARPiEZH2iSTINGagHPK1i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Phase 3 | C5 | ||
| RHH-1546 | Phase 2/3 | C5 | ||
| NVS-3297 | Preclinical | CDK2 | ||
| NVS-4076 | Preclinical | TROP-2 | ||
| MRK-5413 | Phase 1 | GLP-1R | ||
| Talainavolisib | Preclinical | KRASG12D | ||
| Semainavolisib | Phase 2 | PARP | ||
| LEG-9870 | Phase 1 | CGRP | ||
| Polalucimab | Preclinical | PLK4 | ||
| Doxalemzoparlimab | Approved | AHR | ||
| RAR-1117 | Phase 1/2 | TYK2 | ||
| Elraderotide | Phase 1/2 | Tau | ||
| IPN-129 | Approved | PD-L1 | ||
| CIP-2846 | Phase 3 | MALT1 | ||
| EME-9677 | Phase 1 | SMN2 | ||
| MEM-IIT-677 | Preclinical | SHP2 | ||
| SWO-IIT-832 | Approved | Menin | ||
| FOR-6391 | Preclinical | IL-13 | ||
| Motavorutinib | NDA/BLA | PRMT5 | ||
| Doxarapivir | Phase 2 | EGFR | ||
| INH-3643 | NDA/BLA | CD20 | ||
| Polalemzoparlimab | Phase 3 | SMN2 | ||
| IMA-217 | NDA/BLA | HER2 | ||
| VAX-4941 | Phase 1 | BCL-2 | ||
| Voxavorutinib | Phase 2 | Aβ | ||
| MRK-3812 | Phase 3 | CD3 | ||
| Pemiratamab | Phase 2/3 | TYK2 | ||
| Ceviosocimab | Preclinical | WEE1 | ||
| 601-626 | Approved | GIP-R | ||
| Olpatenlimab | Phase 1/2 | AuroraA | ||
| LAE-436 | Preclinical | MET | ||
| 269-6259 | Phase 3 | PCSK9 | ||
| Ribotuximab | Phase 1 | MALT1 | ||
| NCN-3378 | NDA/BLA | PD-L1 | ||
| Pemicilimab | Phase 2 | MET | ||
| HYK-8507 | Phase 1 | GLP-1R | ||
| Sovalemzoparlimab | Phase 2/3 | MET | ||
| Lisonaritide | Preclinical | CD20 | ||
| BER-3725 | Phase 3 | FXIa | ||
| NTC-7741 | NDA/BLA | JAK2 | ||
| Pemimavacamten | Phase 1 | PI3Kα | ||
| Zorilucimab | Approved | PSMA | ||
| Tezetenlimab | Phase 2 | PD-1 | ||
| Gelifutibatinib | Approved | PARP | ||
| NOB-8652 | Approved | MET | ||
| BEA-1452 | Phase 1 | CDK4/6 | ||
| WAT-2618 | Preclinical | IL-17A |
Trials (45)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT03576366 | LLY-9749 | Phase 3 | Terminated |
| NCT04517721 | NVS-3297 | Preclinical | Completed |
| NCT07561614 | NVS-4076 | Preclinical | Terminated |
| NCT06385082 | Semainavolisib | Phase 2 | Recruiting |
| NCT03321170 | Semainavolisib | Phase 2 | Not yet recr... |
| NCT06289144 | LEG-9870 | Phase 1 | Completed |
| NCT06428349 | Doxalemzoparlimab | Approved | Completed |
| NCT05722673 | IPN-129 | Approved | Active |
| NCT08526605 | IPN-129 | Approved | Completed |
| NCT06966819 | IPN-129 | Approved | Completed |
| NCT06973003 | CIP-2846 | Phase 3 | Terminated |
| NCT08288674 | EME-9677 | Phase 1 | Active |
| NCT06271260 | EME-9677 | Phase 1 | Recruiting |
| NCT03830578 | MEM-IIT-677 | Preclinical | Active |
| NCT07169183 | SWO-IIT-832 | Approved | Active |
| NCT04841703 | FOR-6391 | Preclinical | Recruiting |
| NCT05678279 | FOR-6391 | Preclinical | Terminated |
| NCT03361133 | INH-3643 | NDA/BLA | Active |
| NCT06759738 | Polalemzoparlimab | Phase 3 | Completed |
| NCT04701656 | Polalemzoparlimab | Phase 3 | Recruiting |